1261397-71-0

1261397-71-0 structure

Name: Lercanidipine-13C,d3 hydrochloride
Chemical Name: 1-{(3,3-Diphenylpropyl)[(13C,2H3)methyl]amino}-2-methyl-2-propanyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydro-3,5-pyridinedicarboxylate hydrochloride (1:1)
CAS Number: 1261397-71-0
Molecular Formula: C₃₅₁₃CH₃₉D₃ClN₃O₆
Molecular Weight: 652.199
Catalog: Signaling Pathways Membrane Transporter/Ion Channel Calcium Channel
Create Date: 2018-06-23 07:52:46
Modify Date: 2024-01-23 18:50:27
Lercanidipine-13C,d3 (hydrochloride) is the deuterium and 13C labeled Lercanidipine hydrochloride[1]. Lercanidipine hydrochloride is a lipophilic third-generation dihydropyridine-calcium channel blocker (DHP-CCB). Lercanidipine hydrochloride has long lasting antihypertensive action and reno-protective effect[2][3][4].

Name	1-{(3,3-Diphenylpropyl)[(13C,2H3)methyl]amino}-2-methyl-2-propanyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydro-3,5-pyridinedicarboxylate hydrochloride (1:1)
Synonyms	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-[(3,3-diphenylpropyl)methyl-13C-d3-amino]-1,1-dimethylethyl methyl ester, hydrochloride (1:1) 1-{(3,3-Diphenylpropyl)[(13C,2H3)methyl]amino}-2-methyl-2-propanyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydro-3,5-pyridinedicarboxylate hydrochloride (1:1)

Description	Lercanidipine-13C,d3 (hydrochloride) is the deuterium and 13C labeled Lercanidipine hydrochloride[1]. Lercanidipine hydrochloride is a lipophilic third-generation dihydropyridine-calcium channel blocker (DHP-CCB). Lercanidipine hydrochloride has long lasting antihypertensive action and reno-protective effect[2][3][4].
Related Catalog	Signaling Pathways >> Membrane Transporter/Ion Channel >> Calcium Channel Research Areas >> Cardiovascular Disease
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
References	[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [2]. Barrios, V., et al., Lercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile: The LAURA study. Int J Clin Pract, 2006. 60(11): p. 1364-70. [3]. Burnier, M., M. Pruijm, and G. Wuerzner, Treatment of essential hypertension with calcium channel blockers: what is the place of lercanidipine? Expert Opin Drug Metab Toxicol, 2009. 5(8): p. 981-7. [4]. Grassi G, et, al. Lercanidipine in the Management of Hypertension: An Update. J Pharmacol Pharmacother. Oct-Dec 20178(4):155-165.